Remodulin is an injectable version that is used for subcutaneous or intravenous administration. This drug has been on the market for many years and is facing competition from generics ...

Q4 2024 Earnings Call Transcript February 26, 2025 United Therapeutics Corporation beats earnings expectations. Reported EPS is $6.19, expectations were $6.1. Operator: Good morning, and welcome to ...

Moving to Remodulin, we reported fourth-quarter worldwide ... RemUnity Pro is the next generation in subcutaneous pump technology optimized and designed for patients with PAH.

They may be given as intravenous (IV, within a vein) infusions, subcutaneous (under the skin ... Label: Ventavis- iloprost solution. DailyMed. Label: Remodulin- treprostinil injection, solution ...

Treprostinil sodium, which has a metabolic half-life of two to four hours, is supplied as a solution in 20-mL multiple-entry vials for continuous subcutaneous administration at room temperature.

United Therapeutics (NASDAQ:UTHR) Corporation reported its fourth-quarter 2024 earnings, revealing a notable miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS ...

The increase in share-based compensation expense for the quarter ended December 31, 2024, as compared to the same period in 2023, was primarily due to: (1) an increase in stock option expense due ...

Subcutaneous emphysema is the medical term for air becoming trapped in tissues beneath the skin. It is rare, but may occur as a result of trauma, injury, infection, or certain medical procedures ...

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

United Therapeutics (NASDAQ:UTHR) Corporation reported its fourth-quarter 2024 earnings, revealing a notable miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS of ...